Belite Bio, Inc. has kicked off a rolling submission of its new drug application (NDA) to the FDA for tinlarebant, an investigational therapy for the treatment of Stargardt disease.
A rolling submission?! I have so many questions …
Which we’ll answer. But first, let’s get (re)familiarized with Belite.
- See here for a rundown on the biopharmaceutical drug development company and its portfolio of investigational therapies based on a retinal binding protein 4 (RBP4), the sole carrier protein for retinol transport from the liver to the eye.
And its lead candidate?
Tinlarebant is formulated as a once-daily, orally-administered tablet.
Its purpose: To act as an early intervention in maintaining retinal tissue health among patients with Stargardt disease type 1 (STGD1)—as well as dry age-related macular degeneration (AMD) / geographic atrophy (its second investigational indication).
And how does it do this?
To put it simply: By reducing toxic accumulation within the eye that leads to STGD1 development.
- Click here for a more detailed breakdown and description of the process.
Next up: Talk about rolling NDA submission.
What it is: The FDA’s review of sections of an application rather than an entire package submission.
In general: The FDA permits a rolling submission of an NDA or biologics license application (BLA) by companies whose investigational candidates have received certain designations, such as Fast Track or Breakthrough Therapy.
- Notably: This designation also grants them priority review eligibility as well as more frequent meetings with the federal agency.
And in the case of tinlarebant?
The oral tablet has received both Fast Track and Breakthrough Therapy designations for its STGD1 indication (as well as two others).
So what do we know about its NDA package?
The (albeit ongoing) submission includes clinical data from the global phase 3 DRAGON trial (NCT05244304).
- See here for a rundown on its setup, participants, and outcome measures.
As we previously reported in December 2025, the multicenter, double-masked study demonstrated positive topline findings favoring tinlarebant.
Can we get a recap of that data?
Here’s a brief look:
- The study met its primary endpoint, demonstrating “a statistically significant and clinically meaningful" 36% reduction in retinal lesion growth versus placebo
- A “statistically significant treatment effect” was observed in the fellow eye, with a 33.6% lesion growth reduction (p = 0.041)”
- “Tinlarebant was well tolerated with only four treatment-related discontinuations” and none due to non-ocular adverse events
And what was the key takeaway from those findings?
In releasing that phase 3 data, Belite Chairman and CEO Tim Lin, PhD, emphasized tinlarebant's efficacious demonstration in slowing retinal degeneration.
- “This is also the first time that an oral treatment was able to demonstrate a clinically meaningful outcome in retinal degenerative disease,” he stated at the time.
… how about big-picture for tinlarebant?
The oral therapy has the potential to become the first-ever treatment approved by the FDA for Stargardt.
Nice! So, when will this submission be completed?
The company shared a target completion date of Q2 2026.
- Translation: Sometime between now and June 30.
So until then … stay tuned for updates!